• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Open Science

The Alliance expects all research collaborators to make their outputs (materials and knowledge) publicly available, without restriction on use, and to follow the values, principles, and practices in this Open Science Statement. They support the Alliance’s own values on open science.

The table below shows how the values, principles, and practices connect. The numbered practices that follow explain each commitment in more detail.

On this page

Values, principles, and practices  │  Open science practices

Values, principles, and practices

Open Science Statement: values, principles, and practices
Values Principles Practices
Human-centric Fairness Representative; respectful
Inclusive Communications; behaviours; driven by people living with ALS/MND and their communities (PALS/CALS)
Accountability Intellectual property (IP); auditable
Knowledge-sharing Urgency Timely
Transparency Article access
Interoperable Data and code access
Replicable and reproducible Protocols
Trustworthy Reliability Accessible documentation
Private and secure Compliance processes and guidelines
Follow-on research Re-use; attribution and acknowledgement

Practices

  1. Each researcher or project will have a plan for how the principles of open science will be followed, from the start of the project to its end. The plan will describe how the values of human-centric, knowledge-sharing, and trustworthy research will be met.
  2. Where possible, existing human data will be used, so that people living with ALS/MND and their communities do not have to undergo repeat testing if they have given informed consent for their data to be made available under open science principles.
  3. Researchers will post experimental protocols to a protocol-sharing service, such as protocols.io.
  4. All articles resulting from funding must be published in a fully open access journal or posted in an open repository with free, immediate readership rights.
  5. Researchers will seek to place open access results arising from research projects (internal or collaborative) in the public domain. In any Alliance project they undertake (internal or collaborative), researchers will not file any form of patent application or allow a collaborator to restrict the research use of open access project outputs.
  6. Data will be shared according to the FAIR principles: Findability, Accessibility, Interoperability, and Reuse of digital assets.
  7. Researchers will promptly release the associated output data through free and publicly accessible digital repositories, while continuing to comply with all applicable privacy and confidentiality regulations.
  8. Any data, code, and software needed for independent verification of research results must be curated and made freely and publicly available in an established, open repository. This must happen no later than the publication of the first paper based on the data or the end of the grant, whichever comes first.
  9. Research outputs (articles, data, code, and software) resulting from funding must be made available with broad reuse and remixing rights (for example, CC BY or CC0 licences).
  10. Applicants will be encouraged to include the anticipated costs of making their work open in their grant applications.
  11. All researchers and projects will include a data-sharing plan as part of the application process. Compliance checkpoints throughout the term of engagement will proactively collect proof of compliance with this policy, as part of interim and final reports.

Primary Sidebar

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Bob Spurrier, USA

    Bob Spurrier, USA

  • Alejandro Aquino, Argentina

    Alejandro Aquino, Argentina

  • Mike Small, UK

    Mike Small, UK

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • Gisli Jonasson, Iceland

    Gisli Jonasson, Iceland

  • Shera Mukherjee, India

    Shera Mukherjee, India

  • Graham Johnson, Australia

    Graham Johnson, Australia

  • Glen Victor Peters, Australia

    Glen Victor Peters, Australia

  • Malu Araujo Ribeiro, Brazil

    Malu Araujo Ribeiro, Brazil

  • Animesh Kumar, India

    Animesh Kumar, India

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Verónica Isabel Castro Molina, Argentina

    Verónica Isabel Castro Molina, Argentina

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Jack Buzby, USA

    Jack Buzby, USA

  • Jay Epstein, USA

    Jay Epstein, USA

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Len Johnrose, England

    Len Johnrose, England

  • Cassio Fernando da Silva, Brazil

    Cassio Fernando da Silva, Brazil

  • Orly Dichoso, Canada

    Orly Dichoso, Canada

  • Dick Dayton, USA

    Dick Dayton, USA

  • Oscar Mauricio Linares, Colombia

    Oscar Mauricio Linares, Colombia

  • Mike Cels, Canada

    Mike Cels, Canada

  • Sébastien Batiot, France

    Sébastien Batiot, France

  • Chen Yin Xue, Taiwan

    Chen Yin Xue, Taiwan

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Joanne Pratt, Australia

    Joanne Pratt, Australia

  • Andres Estevez Guersznik, Ireland

    Andres Estevez Guersznik, Ireland

  • Jorge Luis Fernández Romero, Mexico

    Jorge Luis Fernández Romero, Mexico

  • Rob Tison, USA

    Rob Tison, USA

  • Marcel R. Wernard, Netherlands

    Marcel R. Wernard, Netherlands

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Joy Blakeley, Australia

    Joy Blakeley, Australia

  • Ana Lilia Rodriguez, Mexico

    Ana Lilia Rodriguez, Mexico

  • Hollister

    Hollister
    hollister

  • Vincent Bourque, Canada

    Vincent Bourque, Canada
    vincent_bourque

  • Jo Knowlton, Scotland

    Jo Knowlton, Scotland

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Brian Parsons, Canada

    Brian Parsons, Canada

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Elkin Gaviria, Colombia

    Elkin Gaviria, Colombia

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • David Bishop, UK

    David Bishop, UK

  • Jason Goodman, USA

    Jason Goodman, USA

  • Philip Brindle, England

    Philip Brindle, England

  • Seckin McGuirk, England

    Seckin McGuirk, England

  • Magdalena Ayala Rodríguez, Mexico

    Magdalena Ayala Rodríguez, Mexico

  • John Russo, USA

    John Russo, USA
    final3878

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login